Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q3 2023 Earnings Presentation
10 slides from Quanterix's earnings presentation, Nov 7, 2023
Slide 1: Q3 2023 Earnings
Q3 2023 Earnings November 7, 2023
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (a
Slide 3: LucentAD p-Tau 217 Blood Test
LucentAD p-Tau 217 Blood Test 93% Accuracy LucentAD p-Tau 217 is a highly The Simoa advantages: ultra 98% Specificity accurate blood test intended for sensitivity that enables blood- 90% Sensitivity assessing amyloid pathology, based detection in the earliest providing both ‘rule-in’ and ‘rule
Slide 4: Corporate Transformation: Assay Redevelopment Roadmap
Corporate Transformation: Assay Redevelopment Roadmap Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 CEO transition Strategic review Stability and Manufacturing Manufacturing Continued bridging Optimized workflow on April 25th completed in July, variance implementation impleme
Slide 5: Continued Scientific Validation Driving Adoption
Neurology Immunology & Oncology Continued Scientific Validation Driving Adoption Infectious Diseases Others P UBLI CATI O NS BI O MARKE RS I NS TRUME NTS ACCE LE RATO R Cumulative Cumulative Cumulative Placements Projects & Revenue, $m 201 2,545 555 953 Number of Drug 538 Trial Projects 168 876 480
Slide 6: Biomarker of neuroinflammation impacting AD testing
Biomarker of neuroinflammation impacting AD testing Simoa GFAP biomarker critical in influencing amyloid-β effects on Tau pathology • An unresolved question is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pat
Slide 7: Q3 2023 Results vs PYQ3
Q3 2023 Results vs PYQ3 (in $ millions) Q3 GAAP Q3 Non-GAAP 2022 2023 2022 2023 Strategic INSTRUMENTS CONSUMABLES ACCELERATOR OTHER Collaborations Revenue 26.6 31.3 26.6 31.3 Revenue Mix 12% 52% 20% 5% 11% Gross Margin $ 10.9 17.8 9.3 15.3 Gross Margin % 41.1% 56.8% 34.9% 48.6% GAAP Revenue Q3 2022
Slide 8: Q3 '23 Cash Balance & Cash Usage
Q3 ‘23 Cash (in millions) -1.9 332.2 $m Cash Balance 0.0 0.8 330.4 & Cash Usage 7.8 6.6 End Q2 FY23 Net Loss Non Working CAPEX End Q3 FY23 Cash Activities Capital and Others* Notes: Ending total cash $330.4M:unrestricted cash balance $201.3M, $126.4M of marketable debt securities and restricted cash
Slide 9: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 GAAP gross profit
Slide 10: Quanterix
Quanterix Discovery Fueled by Ultra-Sensitivity